Christoph Markert

638 total citations
16 papers, 466 citations indexed

About

Christoph Markert is a scholar working on Pharmacology, Pharmacology and Pediatrics, Perinatology and Child Health. According to data from OpenAlex, Christoph Markert has authored 16 papers receiving a total of 466 indexed citations (citations by other indexed papers that have themselves been cited), including 8 papers in Pharmacology, 4 papers in Pharmacology and 4 papers in Pediatrics, Perinatology and Child Health. Recurrent topics in Christoph Markert's work include Pharmacogenetics and Drug Metabolism (7 papers), Eicosanoids and Hypertension Pharmacology (3 papers) and Pharmacological Effects and Toxicity Studies (3 papers). Christoph Markert is often cited by papers focused on Pharmacogenetics and Drug Metabolism (7 papers), Eicosanoids and Hypertension Pharmacology (3 papers) and Pharmacological Effects and Toxicity Studies (3 papers). Christoph Markert collaborates with scholars based in Germany, United States and Switzerland. Christoph Markert's co-authors include Gerd Mikus, Walter E. Haefeli, Jürgen Burhenne, K. Riedel, Antje Blank, Nicolas Hohmann, Alexandra Carls, Alexander I. Alexandrov, Thorsten Lehr and Stephan Urban and has published in prestigious journals such as Journal of Hepatology, Clinical Pharmacology & Therapeutics and British Journal of Clinical Pharmacology.

In The Last Decade

Christoph Markert

16 papers receiving 453 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Christoph Markert Germany 10 166 134 126 82 70 16 466
Alexandra Carls Germany 7 197 1.2× 104 0.8× 117 0.9× 89 1.1× 138 2.0× 13 580
Cheryl Chairez United States 13 152 0.9× 116 0.9× 92 0.7× 36 0.4× 23 0.3× 19 520
Nelia Hernández Uruguay 15 280 1.7× 415 3.1× 232 1.8× 116 1.4× 45 0.6× 47 769
N.G. Ryley United Kingdom 11 116 0.7× 90 0.7× 82 0.7× 81 1.0× 17 0.2× 19 359
P. M. Hooymans Netherlands 15 214 1.3× 99 0.7× 80 0.6× 32 0.4× 123 1.8× 35 875
Alma L. Maldonado United States 9 73 0.4× 158 1.2× 40 0.3× 197 2.4× 86 1.2× 17 445
Dena M. Carbonari United States 14 281 1.7× 151 1.1× 262 2.1× 46 0.6× 25 0.4× 28 548
Elise J. Smolders Netherlands 13 234 1.4× 43 0.3× 204 1.6× 29 0.4× 31 0.4× 31 472
Gurudatt Chandorkar United States 12 185 1.1× 32 0.2× 89 0.7× 72 0.9× 46 0.7× 14 498
Katarina Ilić United States 11 119 0.7× 132 1.0× 18 0.1× 71 0.9× 61 0.9× 25 435

Countries citing papers authored by Christoph Markert

Since Specialization
Citations

This map shows the geographic impact of Christoph Markert's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Christoph Markert with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Christoph Markert more than expected).

Fields of papers citing papers by Christoph Markert

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Christoph Markert. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Christoph Markert. The network helps show where Christoph Markert may publish in the future.

Co-authorship network of co-authors of Christoph Markert

This figure shows the co-authorship network connecting the top 25 collaborators of Christoph Markert. A scholar is included among the top collaborators of Christoph Markert based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Christoph Markert. Christoph Markert is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

16 of 16 papers shown
1.
Junker, Fabian, Uwe Wessels, Stefan Seeber, et al.. (2021). A human receptor occupancy assay to measure anti‐PD‐1 binding in patients with prior anti‐PD‐1. Cytometry Part A. 99(8). 832–843. 11 indexed citations
2.
Suzuki, Yosuke, Walter Mier, Gerd Mikus, et al.. (2017). Ultra-sensitive and selective quantification of endothelin-1 in human plasma using ultra-performance liquid chromatography coupled to tandem mass spectrometry. Journal of Pharmaceutical and Biomedical Analysis. 142. 84–90. 6 indexed citations
3.
Blank, Antje, Christoph Markert, Nicolas Hohmann, et al.. (2016). First-in-human application of the novel hepatitis B and hepatitis D virus entry inhibitor myrcludex B. Journal of Hepatology. 65(3). 483–489. 166 indexed citations
4.
Markert, Christoph, Michael M. Hoffmann, Jürgen Burhenne, et al.. (2014). The Effect of Induction of CYP3A4 by St John's Wort on Ambrisentan Plasma Pharmacokinetics in Volunteers of known CYP2C19 Genotype. Basic & Clinical Pharmacology & Toxicology. 116(5). 423–428. 15 indexed citations
5.
Burhenne, Jürgen, et al.. (2014). Pre‐systemic Elimination of Tilidine: Localization and Consequences for the Formation of the Active Metabolite Nortilidine. Basic & Clinical Pharmacology & Toxicology. 116(2). 129–133. 4 indexed citations
6.
Markert, Christoph, Jürgen Burhenne, Johanna Weiß, et al.. (2014). Lack of a clinically significant interaction of grapefruit juice with ambrisentan and bosentan in healthy adults. International Journal of Clinical Pharmacology and Therapeutics. 52(11). 957–964. 1 indexed citations
7.
Markert, Christoph, Klaus‐Dieter Riedel, Jürgen Burhenne, et al.. (2014). Influence of St. Johnâs wort on the steadystate pharmacokinetics and metabolism of bosentan. International Journal of Clinical Pharmacology and Therapeutics. 52(4). 328–336. 9 indexed citations
8.
Markert, Christoph, Jürgen Burhenne, Michael M. Hoffmann, et al.. (2013). Interaction of ambrisentan with clarithromycin and its modulation by polymorphic SLCO1B1. European Journal of Clinical Pharmacology. 69(10). 1785–1793. 19 indexed citations
9.
Markert, Christoph, Klaus‐Dieter Riedel, Jürgen Burhenne, et al.. (2013). Clarithromycin substantially increases steady‐state bosentan exposure in healthy volunteers. British Journal of Clinical Pharmacology. 77(1). 141–148. 17 indexed citations
10.
Fuchs, Ines, Christoph Markert, Jürgen Burhenne, et al.. (2012). Effect of the CYP3A inhibitor ketoconazole on the PXR-mediated induction of CYP3A activity. European Journal of Clinical Pharmacology. 69(3). 507–513. 29 indexed citations
11.
Markert, Christoph, et al.. (2011). Determining the Time Course of CYP3A Inhibition by Potent Reversible and Irreversible CYP3A Inhibitors Using A Limited Sampling Strategy. Clinical Pharmacology & Therapeutics. 90(5). 666–673. 106 indexed citations
12.
Markert, Christoph, et al.. (2010). Proposal of a new limited sampling strategy to predict CYP3A activity using a partial AUC of midazolam. European Journal of Clinical Pharmacology. 66(11). 1137–1141. 33 indexed citations
13.
Häfner, Verena, Barbara Grün, Christoph Markert, et al.. (2010). Arzneimittelinteraktionen. Der Internist. 51(3). 359–370. 2 indexed citations
14.
Czock, David, et al.. (2009). Pharmacokinetics and pharmacodynamics of antimicrobial drugs. Expert Opinion on Drug Metabolism & Toxicology. 5(5). 475–487. 32 indexed citations
15.
Krause, Werner, et al.. (1999). Zur Messung von Übungs- und Trainingserfolg auf der Grundlage von EEG-Parametern *Friedhart Klix zum 70. Geburtstag gewidmet. Zeitschrift für Pädagogische Psychologie. 13(1/2). 60–73. 2 indexed citations
16.
Bell, Cecil H., Wendell L. French, & Christoph Markert. (1994). Organisationsentwicklung : sozialwissenschaftliche Strategien zur Organisationsveränderung. 14 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Alexandra Carls Breakdown of academic impact, for papers by Cheryl Chairez Breakdown of academic impact, for papers by Nelia Hernández Breakdown of academic impact, for papers by N.G. Ryley Breakdown of academic impact, for papers by P. M. Hooymans Breakdown of academic impact, for papers by Alma L. Maldonado Breakdown of academic impact, for papers by Dena M. Carbonari Breakdown of academic impact, for papers by Elise J. Smolders Breakdown of academic impact, for papers by Gurudatt Chandorkar Breakdown of academic impact, for papers by Katarina Ilić
Rankless by CCL
2026